Can PSA testing become appropriate public health policy?
作者信息
Albertsen Peter
机构信息
Surgery/Urology, UConn Health, Farmington, Connecticut, USA.
出版信息
BMJ Oncol. 2023 Aug 21;2(1):e000168. doi: 10.1136/bmjonc-2023-000168. eCollection 2023.
Abstract
摘要
相似文献
1
Can PSA testing become appropriate public health policy?前列腺特异性抗原检测能否成为合适的公共卫生政策？
BMJ Oncol. 2023 Aug 21;2(1):e000168. doi: 10.1136/bmjonc-2023-000168. eCollection 2023.
2
PSA testing for men at average risk of prostate cancer.对前列腺癌平均风险男性进行前列腺特异性抗原检测。
Public Health Res Pract. 2017 Jul 26;27(3):2731721. doi: 10.17061/phrp2731721.
3
Decision fatigue in low-value prostate cancer screening.低价值前列腺癌筛查中的决策疲劳。
Cancer. 2021 Sep 15;127(18):3343-3353. doi: 10.1002/cncr.33644. Epub 2021 May 27.
4
Improving the Specificity of PSA Screening with Serum and Urine Markers.利用血清和尿液标志物提高前列腺特异性抗原（PSA）筛查的特异性
Curr Urol Rep. 2018 Aug 13;19(10):80. doi: 10.1007/s11934-018-0828-6.
5
Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.挪威男性机会性前列腺特异性抗原检测：公共卫生挑战。
BJU Int. 2024 Jan;133(1):104-111. doi: 10.1111/bju.16211. Epub 2023 Nov 2.
6
Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.协商民主与癌症筛查同意书：关于社区陪审团对男性前列腺特异性抗原筛查知识及参与意愿影响的随机对照试验
BMJ Open. 2014 Dec 24;4(12):e005691. doi: 10.1136/bmjopen-2014-005691.
7
Optimization of PSA screening policies: a comparison of the patient and societal perspectives.PSA 筛查政策的优化：患者和社会观点的比较。
Med Decis Making. 2012 Mar-Apr;32(2):337-49. doi: 10.1177/0272989X11416513. Epub 2011 Sep 20.
8
Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?使用前列腺特异性抗原筛查前列腺癌是一项合适的公共卫生措施吗？
Acta Oncol. 2005;44(3):255-64. doi: 10.1080/02841860410002815.
9
Prostate-specific antigen screening: pro.前列腺特异性抗原筛查：赞成。
Curr Opin Urol. 2010 May;20(3):185-8. doi: 10.1097/MOU.0b013e3283384047.
10
Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.将自由意志家长主义策略应用于前列腺特异性抗原（PSA）筛查决策。
BMC Cancer. 2011 Apr 21;11:148. doi: 10.1186/1471-2407-11-148.
本文引用的文献
1
Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a Prostate Health Check: A Prospective Cohort Study.回复：针对由全科医生发起的前列腺健康检查邀请做出回应的男性中MRI病变的患病率：一项前瞻性队列研究。
Eur Urol. 2024 Apr;85(4):395. doi: 10.1016/j.eururo.2023.11.009. Epub 2023 Nov 25.
2
Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme.设计并实施一项基于人群的有组织的前列腺癌检测计划。
Eur Urol Focus. 2022 Nov;8(6):1568-1574. doi: 10.1016/j.euf.2022.06.008. Epub 2022 Jul 8.
3
Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.前列腺特异性抗原检测作为前列腺癌风险适应性早期检测策略的一部分：欧洲泌尿外科学会2021年立场与建议
Eur Urol. 2021 Dec;80(6):703-711. doi: 10.1016/j.eururo.2021.07.024. Epub 2021 Aug 15.
4
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.基于低强度前列腺特异性抗原的筛查干预对前列腺癌死亡率的影响：CAP随机临床试验
JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154.
5
A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.一项关于临床显著前列腺癌早期检测的随机试验（ProScreen）：研究设计和原理。
Eur J Epidemiol. 2017 Jun;32(6):521-527. doi: 10.1007/s10654-017-0292-5. Epub 2017 Jul 31.
6
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.年轻男性中风险适应性前列腺特异性抗原筛查的前瞻性随机评估：PROBASE试验
Eur Urol. 2013 Dec;64(6):873-5. doi: 10.1016/j.eururo.2013.05.022. Epub 2013 May 14.
7
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.检测血清中前列腺特异性抗原作为前列腺癌的筛查试验。
N Engl J Med. 1991 Apr 25;324(17):1156-61. doi: 10.1056/NEJM199104253241702.
Zotero 插件